11:26 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer after the treatment failed to meet the trial's primary efficacy goals. The company said its investigational drug tiragolumab in combination with Tecentriq and chemotherapy didn't meet the trial's objectives of progression-free survival and overall survival at its first interim analysis. The trial compared the treatment against Merck's Keytruda and chemotherapy. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)


(END) Dow Jones Newswires

07-05-24 1141ET